Exalenz Bioscience Ltd. reported financial results for the second quarter and six months ended June 30, 2018. For the quarter, revenue increased 53% to $3.4 million compared to $2.2 million in the second quarter of 2017. The increase in revenue was primarily driven by penetration of the lab market in the U.S. Operating loss was $1.3 million in the second quarter 2018, compared to an operating loss of $0.9 million in the second quarter 2017. Adjusted EBITDA loss for the second quarter was $0.8 million, similar to the second quarter 2017. Net loss amounted to $1.1 million in the second quarter 2018, compared to a net loss of $1.2 million in the second quarter 2017, or $0.04 per basic and diluted share in both periods. Research and development expenses for the second quarter 2018, net, were $1.0 million compared to $0.6 million in the second quarter 2017. For the six months, revenue increased 67% to $6.7 million, compared to $4.0 million during the same period of 2017. Operating loss for the six months ended June 30, 2018 was $2.3 million, compared to an operating loss of $2.8 million in the same period in 2017. Net loss for the six months ended June 30, 2018 was $2.0 million, or $0.08 per basic and diluted share, compared to $3.0 million, or $0.12 per basic and diluted share, for the six months ended June 30, 2017. Research and development expenses, net, were $1.9 million for the six months ended June 30, 2018 compared to $1.7 million for the same period of 2017.